KEYTRUDA® for high-risk non-muscle invasive bladder cancer
Returning guest Dr. Scot Ebbinghaus discusses the recent (Jan 2020) FDA approval of Merck’s KEYTRUDA® (pembrolizumab) for patients with BCG-unresponsive, high-risk, non-muscle invasive bladder cancer with carcinoma In situ with or without papillary tumors who are Ineligible for or have elected not to undergo cystectomy.
Frequently Asked Questions
What is the main topic discussed in this episode of Health Professional Radio?
This episode covers important developments in healthcare, including updates on Cancer. Health Professional Radio brings you expert insights and analysis on the latest medical news affecting healthcare professionals and patients alike.
How can healthcare professionals benefit from this information?
Healthcare professionals can stay informed about the latest developments in Cancer and related fields, enabling them to provide better patient care. Staying current with medical news helps clinicians make evidence-based decisions in their practice.
Where can I find more information about Cancer?
For more detailed information, listen to the full episode on Health Professional Radio and visit hpr.fm for additional resources. You can also subscribe to our podcast for regular updates on healthcare news and expert interviews.
Dr. Scot Ebbinghaus joined Merck Research Labs Late Stage Oncology Development in 2007. He is currently Vice President and Therapeutic Area Head for Late Stage Oncology Development with responsibilities for overseeing the Keytruda (pembrolizumab) development program as well as responsibility for the development of Lynparza (olaparib) and selumetinib in collaboration with Astra Zeneca. Prior to joining Merck, Dr. Ebbinghaus was an Associate Professor at the University of Arizona in the Department of Medicine, Section of Hematology/Oncology.Dr. Ebbinghaus earned his M.D. degree from the University of Missouri-Kansas City, completed his residency in Internal Medicine and his fellowship in Hematology-Oncology at the University of Alabama-Birmingham. Dr. Ebbinghaus has published over 40 manuscripts, and 5 book chapters in the field of Oncology. In addition to his current responsibilities at Merck, Dr. Ebbinghaus is an attending physician at Fox Chase Cancer Center in Philadelphia in the Thoracic Oncology unit.
Medical Disclaimer
The information provided on this website is for general informational purposes only and is not intended as medical advice. Always consult with a qualified healthcare professional for medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
